Pocket Guide to Chemotherapy Protocols
A quick reference for physicians, nurses, and other healthcare providers treating cancer patents. The updated third edition of the Pocket Guide to Chemotherapy Protocols is spiral bound and arranged alphabetically by cancer type for easy access, and contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies. In each case, the regimens selected are based on the published literature and are used in clinical practice in the medical oncology community.
The Pocket Guide to Chemotherapy continues the success of previous editions by offering cancer care professionals complete, authoritative information in a convenient format.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
1–5 Cisplatin 1–5 Repeat cycle 21 days 5-Fluorouracil 5-fluorouracil Repeat cycle Adjuvant Therapy Bevacizumab bid on days Bleomycin Capecitabine Carboplatin cell carcinoma cell lung cancer Cisplatin combination chemotherapy combination Regimens continuous infusion cycle every 21 cycle every 21–28 Cyclophosphamide Cytarabine Dacarbazine Daunorubicin day 1 5-Fluorouracil day 1 Cisplatin day 1 Cyclophosphamide day 1 Doxorubicin day 1 Etoposide day 1 maximum day 1 Repeat day 1 Vincristine Dexamethasone Docetaxel Doxorubicin Estramustine Etoposide Fludarabine Gemcitabine hours on day Ifosfamide infusion on days Interferon o-2b Irinotecan IV on day Leucovorin lymphoma Mesna metastatic breast cancer Methotrexate mg PO daily mg/day mg/m2 IV mg/m2 IV continuous mg/m2 IV weekly mg/m2 PO bid mg/m2/day IV continuous NEngl non-small cell lung Oxaliplatin Paclitaxel Paclitaxel Paclitaxel patients with advanced Phase II study Phase II trial Prednisone Procarbazine radiation therapy randomized trial Rituximab Semin Oncol Suppl Tamoxifen Topotecan Trastuzumab versus Vinblastine Vincristine Vinorelbine weeks Repeat cycle
Page 172 - McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
Page 174 - Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.
Page 164 - Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291.